Biodyne Co Ltd
KOSDAQ:314930
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8 290
22 800
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biodyne Co Ltd
Cash & Cash Equivalents
Biodyne Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biodyne Co Ltd
KOSDAQ:314930
|
Cash & Cash Equivalents
₩9.7B
|
CAGR 3-Years
48%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Dentium Co Ltd
KRX:145720
|
Cash & Cash Equivalents
₩86.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
I
|
I Sens Inc
KOSDAQ:099190
|
Cash & Cash Equivalents
₩45.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
J
|
Jeisys Medical Inc
KOSDAQ:287410
|
Cash & Cash Equivalents
₩52.9B
|
CAGR 3-Years
32%
|
CAGR 5-Years
115%
|
CAGR 10-Years
N/A
|
|
|
C
|
Classys Inc
KOSDAQ:214150
|
Cash & Cash Equivalents
₩24.3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lutronic Corp
KOSDAQ:085370
|
Cash & Cash Equivalents
₩50B
|
CAGR 3-Years
64%
|
CAGR 5-Years
69%
|
CAGR 10-Years
33%
|
|
Biodyne Co Ltd
Glance View
Biodyne Co., Ltd. engages in the development of cancer diagnosis solutions. The company is headquartered in Seoul, Seoul and currently employs 26 full-time employees. The company went IPO on 2021-03-17. The firm produces and sells LBC diagnostic equipment and diagnostic reagent kits. The firm's LBC equipment include PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63 and PATHPLORER ECO. The firm sells its products in domestic and overseas markets such as Japan, Russia, Portugal and Thailand.
See Also
What is Biodyne Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
9.7B
KRW
Based on the financial report for Dec 31, 2023, Biodyne Co Ltd's Cash & Cash Equivalents amounts to 9.7B KRW.
What is Biodyne Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
47%
Over the last year, the Cash & Cash Equivalents growth was -9%. The average annual Cash & Cash Equivalents growth rates for Biodyne Co Ltd have been 48% over the past three years , 47% over the past five years .
You don't have any saved screeners yet
